Literature DB >> 31801482

Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy.

R Perello1, A Vergara2, E Monclus3, S Jimenez3, M Montero3, N Saubi4, A Moreno2, Y Eto4, A Inciarte4, J Mallolas4, E Martínez4, M A Marcos2.   

Abstract

BACKGROUND: Cytomegalovirus infection dramatically decreased with the introduction of antiretroviral therapy. Whether incidence, clinical characteristics and prognosis of cytomegalovirus in HIV infected patients, has changed over time is. scarcely known.
METHODS: Retrospective single-center study. Patients included in this study were all HIV infected patients that went to our center for any disease, and were diagnosed with cytomegalovirus, during the period 2004-2015. epidemiological, clinical and laboratory patients variables were collected in a clinical database. Clinical characteristics, incidence of cytomegalovirus and predictors of mortality during the study were assessed. Results were considered statistically significant when p < 0.05. All statistical analyses were calculated by SPSS version 20.0 (Chicago, IL,USA).
RESULTS: Fifty-six cases of cytomegalovirus infection, in HIV infected patients were identified during the study period (incidence rate-1.7 cases per 1000 persons/year). The most frequent presentation was systemic illness in 43% of cases. Of note,no patients presented with ophthalmic manifestations. The 30-days mortality was 18%. Predictors of mortality were, in the univariate analysis, admission to the intensive care unit OR 32.4 (3.65-287.06) p = 0.0001, and mechanic ventilation 84 OR (8.27-853.12) p = 0.0001, and ART OR 4.1 (0.97-17.31) p = 0.044. These variables were assessed by multivariate analysis, and only mechanical ventilation was statistically significant (p < 0.05)
CONCLUSION: Incidence of cytomegalovirus infection was higher than described in the antiretroviral therapy era. Clinical presentation has changed. Mechanic ventilation predicted mortality.

Entities:  

Year:  2019        PMID: 31801482     DOI: 10.1186/s12879-019-4643-6

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  6 in total

1.  4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Authors:  Tianyu He; Tiffany C Edwards; Jiashu Xie; Hideki Aihara; Robert J Geraghty; Zhengqiang Wang
Journal:  J Med Chem       Date:  2022-04-04       Impact factor: 8.039

2.  Generalized Pruritus and Gradual Loss of Vision as the Presenting Complaints of Acute HIV Infection: Management Challenges during COVID-19 Pandemic.

Authors:  Shrebash Paul; S M Mahbubur Rahman; Rajibur Rahman; Mahbubur Rahman; Quazi Mamtaz Uddin Ahmed; Rafiqul Alam; Fazle Rabbi Chowdhury
Journal:  Case Rep Infect Dis       Date:  2021-12-01

3.  8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Authors:  Eunkyung Jung; Ryuichi Majima; Tiffany C Edwards; Ruben Soto-Acosta; Robert J Geraghty; Zhengqiang Wang
Journal:  ChemMedChem       Date:  2022-08-10       Impact factor: 3.540

4.  Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV).

Authors:  Sameera Senaweera; Tiffany C Edwards; Jayakanth Kankanala; Yan Wang; Rajkumar Lalji Sahani; Jiashu Xie; Robert J Geraghty; Zhengqiang Wang
Journal:  Acta Pharm Sin B       Date:  2021-08-23       Impact factor: 14.903

5.  Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers.

Authors:  Giulia Caligaris; Mattia Trunfio; Valeria Ghisetti; Jessica Cusato; Marco Nigra; Cristiana Atzori; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Diagnostics (Basel)       Date:  2021-05-12

Review 6.  Elevated Risk of Venous Thromboembolism in People Living with HIV.

Authors:  Quan Zhang; Fei Peng; Meizhi Li; Qiong Yi; Wei Tang; Shangjie Wu
Journal:  Viruses       Date:  2022-03-12       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.